Pharmaceuticals, Biotechnology and Life Sciences
UBM EMEA announces the rebranding and relocation of CPhI Istanbul into CPhI Middle East & Africa, which will open next year (3-5 September 2018) at ADNEC Centre, Abu Dhabi, United Arab Emirates (UAE).
ASIT biotech, a Belgian clinical-stage biopharmaceutical company could soon market its gp-ASIT+ grass pollen product, as it showed positive results in Phase III clinical trial in grass pollen rhinitis.
Former Allergan boss David Pyott signed as special advisor to Sienna Biopharmaceuticals, a privately held, clinical-stage medical dermatology and aesthetics company.
Realm Therapeutics has won FDA’s approval for its IND application to proceed with Phase II clinical trial for atopic dermatitis (AD) drug.
TopiVert Pharma has finished dosing of the first subjects in a Phase 1 study of its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).
US Food and Drug Administration (FDA) has approved AstraZeneca’s once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes.
Oxford BioMedica, a leading gene and cell therapy group, announces that Stuart Paynter will join Oxford BioMedica as Chief Financial Officer to succeed Tim Watts, who has decided to retire from full time executive roles.
Johnson & Johnson has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott for $4.325 billion
Matinas BioPharma Holdings has been approved for listing on the New York stock exchange, and will be trading under the symbol “MTNB” starting from March 2, 2017.